1. Home
  2. DGX vs RPRX Comparison

DGX vs RPRX Comparison

Compare DGX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$232.29

Market Cap

26.2B

Sector

Health Care

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

BUY

Current Price

$56.62

Market Cap

25.9B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DGX
RPRX
Founded
1967
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2B
25.9B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
DGX
RPRX
Price
$232.29
$56.62
Analyst Decision
Buy
Buy
Analyst Count
17
8
Target Price
★ $247.73
$65.13
AVG Volume (30 Days)
878.7K
★ 2.8M
Earning Date
10-22-2026
11-04-2026
Dividend Yield
1.47%
★ 1.65%
EPS Growth
★ 13.78
N/A
EPS
★ 5.08
0.71
Revenue
★ $11,035,000,000.00
$2,378,193,000.00
Revenue This Year
$8.81
$47.32
Revenue Next Year
$4.70
$8.70
P/E Ratio
★ $45.49
$81.17
Revenue Growth
★ 11.78
5.06
52 Week Low
$171.18
$35.23
52 Week High
$248.84
$64.38

Technical Indicators

Market Signals
Indicator
DGX
RPRX
Relative Strength Index (RSI) 43.23 34.15
Support Level $229.36 $56.36
Resistance Level $248.02 $58.84
Average True Range (ATR) 4.99 1.06
MACD -1.32 -0.20
Stochastic Oscillator 22.75 19.56

Price Performance

Historical Comparison
DGX
RPRX

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: